Overview

A Study of MK-2225 in Healthy Participants (MK-2225-003)

Status:
COMPLETED
Trial end date:
2025-07-14
Target enrollment:
Participant gender:
Summary
The purpose of the study is to learn about the safety of MK-2225, including how well people tolerate it. Researchers also want to learn what happens to different doses of MK-2225 in a person's body over time.
Phase:
PHASE1
Details
Lead Sponsor:
Merck Sharp & Dohme LLC